Stan Bleszynski's heretical ideas on science, optimal human nutrition etc.
@stanble
2008 - Age of Awakening / 2016 - Age of disclosures / 2021 - Age of Making Choices & Separation / Next Stage - Age of Reconnection and Transition! / 2024 - Two millenia-old Rational Collectivist societal cycle gives way to the Self-Empowered Individualism. / 2025 Golden Age begins
Reblogged from JAMES-LYONS-WEILER substack article
Quote:
New Study: How Ivermectin Kills Prostate Cancer Cells
I was doing the background research for my lecture on Prostate Cancer in my IPAK-EDU Course, The Biology of Cancer, looking for treatments that enhance genomic instability - and Guess What?
I spent the first semester of my course, The Biology of Cancer, reviewing all of the aspects of The Hallmarks of Cancer. This morning, firing up Pubmed to continue preparing my lecture prostate cancer, I found this gem of a study, which happens to be a collaboration between my former employer, The University of Pittsburgh, and Southern Medical University-Guangzhou. I don’t know the authors:
Title: Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer
The authors exposed various prostate cancer cells lines to Ivermectin and found that ivermectin binds to two proteins: FOXA1 and Ku70/Ku80. This leads to the inhibition of androgen receptor (AR), E2F1 expression, and DNA damage repair activity. The cells stopped dividing (G0/G1 cell cycle arrest), experience extensive DNA damage, and die.
A retrospective study of the rates of cancer and rates of death from cancer among unvaccinated people who prophylactically used Ivermectin over a long period of time vs those who did not is in order.
Conclusion
Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin. This dose-response efficacy reinforces the prophylactic effects of ivermectin against COVID-19.
You can make a weak or moderate recommendation solely on observational trials data! Plus, the unparalleled safety profile of ivermectin combined with the existing highly positive data in over 1,000 patients and 12 randomized controlled trials should have led to at a minimum a weak recommendation in the midst of a humanitarian catastrophe (the winter of 2020-2021 was particularly brutal in U.S hospitals).
However, had they done that, the entire country’s (and world’s) doctors would have started treating all COVID patients with ivermectin. They knew they could not do provide any recommendation stronger than “neutral.” Plus Fauci would never let that happen (remember, as a public servant, it is well documented that he has worked in the service of the pharmaceutical industry his entire career). So that's what they did.
There was a lot of attention on Ivermectin after my testimony so they had to do something. Knowing what I know now of the immense powers of Big Pharma, I suspect that even if they had delivered a “weak” recommendation for use, it may not have moved the needle much. I say this largely because the market competitors of ivermectin had many other tactics they could use (and did) to prevent widespread adoption (i.e. their devastatingly effective “horse dewormer” public relations campaign deployed using synchronized messaging amongst all major TV, radio, and print outlets. Plus they probably knew that the WHO was going to update their recommendations based on Andy and his team's continued research over the next two months, so they punted. I would argue that they knew the fix was in at the WHO already. But this is when things get even crazier.
Paul and I read his posted pre-print review and were shocked. The conclusions did not match the data. For the first time in my career, I found myself reading a scientific manuscript by a researcher presenting such profound and compelling data yet whose conclusions argued against the findings. If there is anything that scientists and researchers tend to do when publishing original work, is that they tend to over-interpret the potential importance and impact of their data. But here there was such overwhelmingly positive data yet the paper and conclusions read as if the conclusions were very uncertain and too “heterogenous” to act on.
In addition, it was poorly written, with repeated expressions of the limitations of the data including false statements about how effective concentrations could not be reached with standard dosing (something we knew Andy knew was false). In addition the conclusion did not match the data presented. Paul and I immediately suspected scientific misconduct was occurring so we immediately wrote to Andy with our concerns and provided him with a complete peer-review of his paper containing our many comments and recommendations for changes. We demanded that he immediately take down his paper and implement the suggested revisions to be more consistent with the existing data. Among other demands, we asked that he remove the statements about how effective concentrations could not be reached in the blood with standard doses (we had as a group presented data disproving that to the NIH). Further we called out the numerous irregularities in his paper like the repetitive citation of the “limitations” of the data presented.
We knew something was off, like really off and so did Tess. But we didn’t know exactly what was going on “behind the scenes.” It was not until a year later when we found out who and what were behind these manipulations trying to distort and suppress the evidence of efficacy of ivermectin. Those details were uncovered by a man named Phil Harper. I consider him a polymath with a diverse background of interests and accomplishments having worked in journalism and documentary filmmaking among other pursuits. He was a UK citizen and had been living in India during the early pandemic and was shocked when he returned to UK in mid-to-late 2021 and found a country without any early treatment strategy that was instead attacking, suppressing, and legislating against ivermectin which was in wide use at the time in India. So he dug into the topic. Note his Substack is called “the Digger” and it is masterful. What he discovered about the events that occurred over those weeks is absolutely stunning. I credit his work and his publications on his Substack with much of the finer and personal details of what I will present as having happened over those weeks. Please read it. Please also consider donating to help fund his proposed documentary project called “The Research Cartel.” I believe it will have major impacts on exposing all that is rotten in medical research.
It is an astounding video. Andy actually admitted to Tess that his “sponsors” influenced the writing of the paper. Tess asked him for names but he refused. And we all know that whoever had altered that paper they were not listed as an author of the paper. This was clear scientific misconduct. She included the most relevant parts of this meeting in a devastatingly effective video called “A Letter to Andrew Hill” which essentially covers all of the most relevant and impactful events that I am detailing in these posts. I have included it at the end of Part 2. It is a must watch and likely communicates more than I ever can with words. Please hang in, hold, read this through, and then watch the video.
So, who was the person making all the changes attacking ivermectin in Andy’s paper? Not mentioned during the recorded meeting with Tess Lawrie and Andrew Hill, but Hill later referenced a person named Dominique Costagliola. What is fascinating is that Phil Harper, acting as a journalist (which he is), actually got Andrew Hill to meet him for coffee in London to do an interview about ivermectin. He purposely gave Andy the sense that he was a “friendly” reporter doing a hit piece on ivermectin. By the time of that interview, Andy had been actively attacking the evidence in support of ivermectin. I suspect he was probably eager to take advantage of yet another opportunity to please his paymasters. Phil even got Andy to confirm that he had been discussing the paper with Dominique Costagliola during that earlier time period and that she had been advising him in some way. Twitter users quizzed her on it and she too confirmed it.
So what did Phil find out about Dominique Costagliola?
She is the Deputy Director of the Pierre Louis Institute of Epidemiology and Public Health in France.
She speaks English as a 2nd language (this is important as the other “influencer” of Andy that you will soon meet below is English)
She had a history of attacking ivermectin, starting very soon after my testimony on the 19th of December 2020, as evidenced in this article “fact checking” the idea that ivermectin was effective in COVID. That article essentially started the narrative refrain we hear about still to this day - “the trials were are small, low quality” and that “proper, large rigorous” (i.e. Pharma controlled) trials are needed to validate the findings.
She is a Pharma-conflicted individual just like all the other research and regulatory agency operatives working against ivermectin. She receives lecture fees from nearly every corporation with a competing product against ivermectin. Janssen, Gilead, Merck-Sharp and Dome (biopharmaceutical company), Viiv, Innavirvax and Merck Switzerland. She has taken money in the form of lecture fees, personal fees, and travel and meeting expenses.
I maintain that she is the one who inserted that bizarre weird phrase that no researcher or scientist would ever put in their conclusion, you know the one about “regulatory approval.” Phil discovered that in March 2021, she even used the same phrase in a tweet:
What Phil discovered next, to me, is the “Scoop of the Century” given that I call what these people and others (Hi Billy G!) did to ivermectin, the “Crime of the Century.” Phil discovered who was really in control of both Andy and the evidence supporting ivermectin. It was the Professor that Andy had mentioned to me in our first ever conversation.
Phil discovered the Professor’s identity by simply looking at the “meta data” embedded in the PFD file of the preprint paper. It was finalized on the computer of Professor Andrew Owen of the University of Liverpool in the days leading up to the posting. Whoa. Thus, this was the same Professor that had suggested to Andy to “look into ivermectin” in November of 2020.
On what evidence do I make this claim? Not only the fact that Andy’s paper was doctored on the computer of Professor Owen but also on his insane conflicts of interest against ivermectin. Again, I maintain he was getting Andy to do “opposition research” without Andy knowing he was working for the other side at the time. Owen’s Big Pharma conflicts with competing products to ivermectin are unparalleled. Costagliola’s pales in comparison.
They reported 70 deaths per 1000 in the standard-of-care treated patients vs. 14 deaths per 1000 in ivermectin treated patients. An 80% reduction in mortality. Let me repeat that. An 80% reduction in mortality. Remdesivir doesn’t do that. Paxlovid doesn’t do that. Molnupiravir doesn’t do that. Monoclonal antibodies don’t do that. And Owen had conflicts with three of these “competitors” (it was not even close to a competition, except in price and profit potential).
The study found no difference between the treated group versus the control group in the viral load detected by PCR, but treated patients recovered twice as fast.
Title: "The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial", by Carlos Chaccour et al., The Lancet, January 19, 2021
Abstract
Over the past decade, the global scientific community have begun to recognize the unmatched value of an extraordinary drug, ivermectin, that originates from a single microbe unearthed from soil in Japan. Work on ivermectin has seen its discoverer, Satoshi Ōmura, of Tokyo’s prestigious Kitasato Institute, receive the 2014 Gairdner Global Health Award and the 2015 Nobel Prize in Physiology or Medicine, which he shared with a collaborating partner in the discovery and development of the drug, William Campbell of Merck and Co. Incorporated. Today, ivermectin is continuing to surprise and excite scientists, offering more and more promise to help improve global public health by treating a diverse range of diseases, with its unexpected potential as an antibacterial, antiviral and anti-cancer agent being particularly extraordinary.
Ivermectin effectively suppresses the proliferation and metastasis of cancer cells and promotes cancer cell death at doses that are nontoxic to normal cells.
Ivermectin shows excellent efficacy against conventional chemotherapy drug-resistant cancer cells and reverses multidrug resistance.
Ivermectin combined with other chemotherapy drugs or targeted drugs has powerful effects on cancer.
The structure of crosstalk centered on PAK1 kinase reveals the mechanism by which ivermectin regulates multiple signaling pathways.
Ivermectin has been used to treat parasitic diseases in humans for many years and can quickly enter clinical trials for the treatment of tumors.
Abstract
Ivermectin is a macrolide antiparasitic drug with a 16-membered ring that is widely used for the treatment of many parasitic diseases such as river blindness, elephantiasis and scabies. Satoshi ōmura and William C. Campbell won the 2015 Nobel Prize in Physiology or Medicine for the discovery of the excellent efficacy of ivermectin against parasitic diseases. Recently, ivermectin has been reported to inhibit the proliferation of several tumor cells by regulating multiple signaling pathways. This suggests that ivermectin may be an anticancer drug with great potential. Here, we reviewed the related mechanisms by which ivermectin inhibited the development of different cancers and promoted programmed cell death and discussed the prospects for the clinical application of ivermectin as an anticancer drug for neoplasm therapy.
I am posting it as a place-holder to prompt a further digging.
The original video presentation, quoting from memory because the original video depictued in the screenshot below, has been since deleted by youtube (and my account has been blocked by Twitter).
The presenter discussed an in-vitro study using human cultured tissues, with and without Нуdrохуснlоrоquin : (1) lung cancerous tissue (HeLa) and (2) kidney tissue (non-cancerous). The study found that c0rоna virus (normal cv non c19) would attack the lung and the kidney tissue without hcq, while the virus would only attack the cancerous lung tissue but not the non-cancerous kidney tissue when hcq is added.
Further and additional referenced, not the actual presentation:
Quote: Since inhibition of SERCA is a mechanism of action that has been used to target solid tumors, thapsigargin has attracted research interest. A prodrug of thapsigargin, mipsagargin, is currently undergoing clinical trials for the treatment of glioblastoma.
...
The task has been taken on by Samuel Denmeade, an oncologist at Johns Hopkins University in Baltimore. He and his team spent 15 years engineering an analogue of thapsigargin, the active ingredient in the plant, to fight cancer cells exclusively.
Thapsigargin typically works by passing through cell membranes and shutting down calcium pumps – essential for cell survival – on the inside of cells. Denmeade’s team modified the thapsigargin molecule by adding an extra peptide chain which prevents the toxin from entering cells. That is, until it encounters PSMA – an enzyme commonly found on the surface of many prostate cancer cells. PSMA cleaves the extra chain off the toxin, setting it free to do its devastating business.
Precision killer
While traditional chemotherapy drugs only target cells undergoing rapid growth, this new toxin is a generalist, destroying not just the cancer cells currently growing, but also those lying dormant as well as non-cancer cells recruited to help the tumour grow.
...
Note: a Patent is not a proof that the invention works!
Quotes:
ABSTRACT The present invention provides methods and compositions for the treatment of DNA damage related disorders. One embodiment is a method for the inhibition of Side effects asSociated with chemotherapeutic and radiotherapeutic agents using chloroquine compounds. Another embodiment is a method for treatment and/or prevention of lethal or Sub-lethal radiation toxicities associated with terrorist acts or war.
BRIEF DESCRIPTION OF THE FIGURES 0007 FIG. 1 shows a Kaplan-Meier survival curve of C57/BL6 mice after exposure to 8 Gy total body irradiation (TBI). Half of the cohort received a dose of chloroquine (dashed line) by either i.p. injection (1.75 mg/kg or 3.5 mg/kg) or in their drinking water (3.5 mg/kg or 7 mg/kg) the day before the TBI. The one mouse which died in the chloroquine-treated group received 1.75 mg/kg by i.p. injection.
0008 FIG. 2 shows that chloroquine treatment enhances survival after TBI by enhancing recovery of hematopoietic progenitor cells. Five mice received 3.5 mg/kg chloroquine (C) by i.p. injection 24 and 4 hours prior to TBI (bars with diagonal Stripes). Five mice received no chloroquine (stippled bars). Fourteen days after irradiation, the cellular ity (open bars) of hematopoietic tissues (spleen, thymus, bone marrow) was assessed by a blinded observer on a scale of 0-3 with 3 being normal cellularity. The bars represent the average cellularity of the tissues from the 5 mice in each group.
0009 FIG.3 shows a Kaplan-Meier survival curve of AT mice after exposure to 8 GyTBI. Half of the cohort received a dose of 3.5 mg/kg chloroquine (CHL; dashed line) by i.p. injection 24 and 4 hours prior to the TBI.
0010 FIG. 4 demonstrates that chloroquine treatment prevents the development of tumors in Eul-myc mice. After weaning, a cohort of transgenic mice expressing the c-myc oncogene were started on chloroquine (CHL) at 7.0 mg/kg in the drinking water ((+), solid line). Within 100 days, all of the mice with no drug in the water had died of leukemia, while none of the cohort of mice on drug had Succumbed. The latter group of mice was then divided into two groups (timing of this event depicted by heavy arrow), one group of which was taken off of chloroquine ((-), dashed line) and the other group of which was started on i.p. injections of 3.5 mg/kg of chloroquine once a week. Within a month, all of the mice taken off of chloroquine had developed malignan cies and all of the mice on the weekly i.p. injections remained tumor-free for months.
0011 FIG. 5 illustrates that chloroquine treatment reduces the development of tumors in mice injected with the potent chemical carcinogen, 3-methylcholanthrene (3-MC). Chloroquine (CHL, 3.5 mg/kg) was given by i.p. injection 24 and 4 hours prior to 3-MC injection in 30 mice and 30 mice received the carcinogen with no chloroquine pretreat ment. The percentage of animals remaining tumor-free is plotted. Statistical significance, log rank test P-0.0001.
0012 FIG. 6 demonstrates that chloroquine treatment reduces the development of tumors in mice exposed to ionizing radiation in a protocol that induces thymic lym phomas. Chloroquine (CHL, 3.5 mg/kg) was given by i.p. injection 24 and 4 hours prior to irradiation in four Successive weeks and animals were subsequently observed for the development of tumors. Statistical Significance, log rank test P=0.0012.
0013 FIG. 7 shows tumor incidence in wildtype mice receiving either placebo or CHQ before 3-MC injection. CHQ markedly protects from tumor development.
0014 FIG. 8 shows tumor incidence in ATM-null mice receiving either placebo or CHQ before 3 MC injection. CHQ does not protect from tumor development.
0015 FIG. 9 shows tumor incidence in p53-null mice receiving either placebo or CHQ before 3 MC injection. CHQ does not protect from tumor development.
0016 FIG. 10 demonstrates the efficacy of two chloroquine compounds in preventing, in Varying degree, the change in coat color in mice treated with 8 GY radiation.
Abstract
Objective: To describe outcomes of patients with coronavirus disease 2019 (COVID-19) in the outpatient setting after early treatment with zinc, low dose hydroxychloroquine, and azithromycin (the triple therapy) dependent on risk stratification. Design: Retrospective case series study. Setting: General practice. Participants: 141 COVID-19 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the year 2020. Main Outcome Measures: Risk-stratified treatment decision, rate of hospitalization and all-cause death. Results: Of 335 positively PCR-tested COVID-19 patients, 127 were treated with the triple therapy. 104 of 127 met the defined risk stratification criteria and were included in the analysis. In addition, 37 treated and eligible patients who were confirmed by IgG tests were included in the treatment group (total N=141). 208 of the 335 patients did not meet the risk stratification criteria and were not treated. After 4 days (median, IQR 3-6, available for N=66/141) of onset of symptoms, 141 patients (median age 58 years, IQR 40-60; 73% male) got a prescription for the triple therapy for 5 days. Independent public reference data from 377 confirmed COVID-19 patients of the same community were used as untreated control. 4 of 141 treated patients (2.8%) were hospitalized, which was significantly less (p less than 0.001) compared with 58 of 377 untreated patients (15.4%) (odds ratio 0.16, 95% CI 0.06-0.5). Therefore, the odds of hospitalization of treated patients were 84% less than in the untreated group. One patient (0.7%) died in the treatment group versus 13 patients (3.5%) in the untreated group (odds ratio 0.2, 95% CI 0.03-1.5; p=0.16). There were no cardiac side effects. Conclusions: Risk stratification-based treatment of COVID-19 outpatients as early as possible after symptom onset with the used triple therapy, including the combination of zinc with low dose hydroxychloroquine, was associated with significantly less hospitalizations and 5 times less all-cause deaths.
(CNN)A surprising new study found the controversial antimalarial drug hydroxychloroquine helped patients better survive in the hospital. But the findings, like the federal government's use of the drug itself, were disputed.
A team at Henry Ford Health System in southeast Michigan said Thursday their study of 2,541 hospitalized patients found that those given hydroxychloroquine were much less likely to die.
Dr. Marcus Zervos, division head of infectious disease for Henry Ford Health System, said 26% of those not given hydroxychloroquine died, compared to 13% of those who got the drug. The team looked back at everyone treated in the hospital system since the first patient in March.
"Overall crude mortality rates were 18.1% in the entire cohort, 13.5% in the hydroxychloroquine alone group, 20.1% among those receiving hydroxychloroquine plus azithromycin, 22.4% among the azithromycin alone group, and 26.4% for neither drug," the team wrote in a report published in the International Journal of Infectious Diseases.
...
It's a surprising finding because several other studies have found no benefit from hydroxychloroquine, a drug originally developed to treat and prevent malaria. President Donald Trump touted the drug heavily, but later studies found not only did patients not do better if they got the drug, they were more likely to suffer cardiac side effects....
Comment (by Heretic): some of those negative studies that resulted in governments of many countries and WHO abandoning this line of therapies, most notably the one published recently by The Lancet were based on fraud and has since been recalled. (P.S., CNN - "purveyors of fake news" as they say, when I find a more credible link I will post it, but for now, sorry...)
------------------ Follow up story (5-July-2020 -------------------------
Medical establishment has been recently attempting to suppress a common drug against the recent flu outbreak. The drug that was recommended by the US president - hydroxychloroquine. The suppression involved publishing a completely fabricated negative trial paper using fraudulent data (see the recently super-quickly published and equally quickly retracted Lancet paper) while promoting some alternative drugs and hypothetical (future) vaccines by the top US health official Dr. Fauci.
One of such drug is Remdesivir produced by Gilead Sciences. Now it turns out that Remdesivir seems to be ineffective, see below:
... and the company or their backers in the medical establishment attempted to cover it up:
... but there are also some new doubts cast on the Remdesivir trial conducted by Dr. Fauci's company itself.
One such doubt is the trial specification removing "Death" from the set of sought outcomes.
At the same time, the two recently disclosed or published studies on hydroxychloroquine showed dramatic and positive outcome on patients' recovery. As you can see in the original section posted above. For example mortality reductions by 2 to 5 times!
So it turns out, the president of the United states was correct while his top medical advisor was wrong (at best) or may even end up proven malfaisant in the future.
Youtube video:
"BREAKING: REMDESIVIR STUDY MANIPULATED?",
posted May 4, 2020
by "The HighWire with Del Bigtree"
(Note: I recommend watching it soon, it might not remain for very long!) Update 1-Aug-2020 - Youtube just "torched" Dell Bigtree's account last week! I hope He Will be Back!
...Treatment with HCQ-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days (odds ratios 95% CI 0.38 0.27–0.54) and shorter duration of viral shedding (time to negative PCR: HR 1.29 1.17–1.42). QTc prolongation (greater than 60 ms) was observed in 25 patients (0.67%) leading to the cessation of treatment in 12 cases including 3 cases with QTc greater than 500 ms. No cases of torsade de pointe or sudden death were observed.
Conclusion
Although this is a retrospective analysis, results suggest that early diagnosis, early isolation and early treatment of COVID-19 patients, with at least 3 days of HCQ-AZ lead to a significantly better clinical outcome and a faster viral load reduction than other treatments.
As Doctor Jim Meehan conjectures, these studies are designed to fail. He believes this is being done to contrive a message to manipulate, mislead and deceive the masses, and that public health is being subverted by commercial bias and political agendas. ...
And these excessive doses are not only making it impossible to assess the therapeutic benefits of HCQ for COVID-19 patients accurately. They are clearly hastening the deaths of many in the study who have been unaccountably administered dangerous amounts of a highly effective drug with a 70-year record of safety and efficacy. A highly salient point made by Del Bigtree of ICAN is that well over 5 million doses of hydroxychloroquine were taken in the United States in 2107 [2017?] for the treatment of lupus, arthritis, and malaria. If the FDA is so concerned about adverse effects associated with HCQ, why wait until now to revoke its use when it was used so widely and so effectively just a few years ago? ...
--------------------- Update 1-Sep-2020 ----------------------------------
Link to the article: "Covid Analysis" This is a compilation of 84 published studies, 49 of them peer-reviewed (all referenced and linked):
Small early terminated late stage (60% on oxygen) RCT in France showing 46% lower mortality.
mortality at 28 days relative risk RR 0.54 [0.21-1.42]
combined mortality/intubation at 28 days relative risk RR 0.74 [0.33-1.70]
I was aware of such a case with the same puzzling symptoms, which had been described in 2014 by Swedish pneumologists in a young patient from Nigeria who had died of the disease. At that time, an enzyme deficiency was suspected and actually found to be a possible cause after death, which occurs in many regions of Africa in 20 - 30% of the population.
It is the so-called glucose-6-dehydrogenase deficiency, or "G6PD deficiency", one of the most common genetic peculiarities, which can lead to threatening haemolysis (dissolution of red blood cells), mainly in men, when certain drugs or chemicals are taken. The following map shows the distribution of this deficiency (Source and explanations here).
[pic]
This hereditary trait is particularly common among ethnic groups living in areas with malaria. The modified G6PD gene offers advantages in the tropics. It makes its carriers resistant to malaria pathogens. However, G6PD deficiency is also dangerous if those affected come into contact with certain substances found in, for example, field beans, currants, peas and a number of medicines.
These include acetylsalicylic acid, metamizole, sulfonamides, vitamin K, naphthalene, aniline, malaria drugs and nitrofurans. The G6PD deficiency then leads to a disruption of the biochemical processes in the red blood cells and – depending on the dose – to mild to life-threatening haemolysis. The debris of the burst erythrocytes subsequently leads to microemboli, which block small vessels throughout the organs. What had caused the illness and death of the young man from Nigeria remained unclear at the time.
An alarming discovery
I looked at the drugs that can cause severe hemolysis in G6PD deficiency and got really scared. One of the substances that is called very dangerous in all forms of this enzyme deficiency is the anti-malarial drug hydroxychloroquine (HCQ).
But this is precisely the substance that Chinese researchers in Wuhan have been recommending against SARS since 2003. Along with the virus from Wuhan, HCQ now came back to us as one of the therapeutic options and was accepted as such. At the same time, HCQ was recommended as a promising agent against Covid-19 for further clinical trials with the support of WHO and other agencies.
According to reports, production of this drug is to be increased in Cameroon, Nigeria and other African countries. India is the largest producer of HCQ and exports it to 55 countries. Werner Baumann, Chairman of the Board of Management of Bayer AG, announced at the beginning of April that "various investigations in laboratories and clinics" had provided first indications that chloroquine might be suitable for the treatment of corona patients. The company then provided several million tablets.
There are now hundreds of trials worldwide, planned or ongoing by different sponsors, in which HCQ is used alone or together with other drugs. When I looked at some large studies to see if patients with G6PD deficiency were excluded, I found no evidence of this in most study plans. In the USA, for example, a large multi-center study with 4,000 volunteers from healthy medical staff is being prepared. Here, however, the term "hypersensitivity" is only used in general terms, as is the case with all drugs with regard to allergic reactions. In a chloroquine/hydroxychloroquine study by Oxford University (NCT04303507) with a planned 40,000 participants, the risk of G6PD deficiency is also not mentioned. In another large study by the Pentagon, though, there is an explicit warning to exclude G6PD deficiency patients from the study.
The following graph, based on information from the WHO database, shows how many studies on Covid-19 and HCQ have been initiated – and how few of them take enzyme deficiency into account.
[pic]
Mostly only the cardiac complications of chloroquine or hydroxychloroquine are mentioned, which in Brazil led to the premature termination of a study with 11 deaths of 81 subjects. However, it seems that worldwide little attention is paid to this further serious side effect. In addition, due to the lack of alternatives, HCQ has been tolerated and massively applied in many countries since the beginning of the year as part of a so-called "compassionate use". In medicine, compassionate use refers to the use of not yet approved drugs in emergency situations.
Conspicuous clusters
During this research, more and more results of more precise evaluations of the deaths in especially affected cities were received. In New York and other cities in the USA, it was reported that the vast majority of fatalities were African Americans – twice as many as could be expected based on the proportion of the population.
Also from England, where the mortality data from Euromomo shows an increasing death rate since the beginning of April, it was reported that 35% of about 2000 seriously ill people, twice as many as expected, came from ethnic "minorities" ("black, Asian or other ethnic minority"), including doctors and medical staff.
A major doctor's death in Italy remains in urgent need of clarification. The death of about 150 doctors and only a few female doctors is associated with Covid-19. Although age may have played a role in many of these cases, it should be noted that a high prevalence of G6PD deficiency has also been described for some regions of Italy and that in Italy up to 71% of those who tested positive with PCR, as well as the staff, had a prophylactic high level of HCQ. The same applies to Spain. Among the first 15 Covid-19 deaths in Sweden, there were 6 younger migrants from Somalia.
Deadly combination
Therefore the frightening result of my research is that typical severe courses with haemolysis, microthrombi and shortness of breath without typical signs of pneumonia occur more frequently where two factors come together:
Many patients with ancestors from malaria countries with G6PD deficiency
Prophylactic or therapeutic use of high-dose HCQ
This is exactly what is to be expected in Africa, and this is already the case everywhere where migration is causing a large proportion of the population coming from malaria countries. The following diagram shows the process flow schematically.
[pic]
Cities such as New York, Chicago, New Orleans, London, or even large cities in Holland, Belgium, Spain and France are such centers. If the test is widely used in these migration hotspots and is expected to be positive in about 10 to 20% of the population, many people from the G6PD countries will also be among them. If they are then treated with high-dose HCQ, either prophylactically or as part of a "compassionate" use, as planned, then those severe clinical pictures will also be evoked in young people, as has been presented to us by the sensational press, and which keep our fear of Covid-19 alive.
It is unknown how many times this deadly combination has already led to victims. There has been no discussion of the issue among those responsible in the WHO and in governments. There is also a frightening lack of knowledge and sense of responsibility among doctors who are accountable for the treatment of Covid-19 patients or for the staff treating them.
Once again: This connection applies not only to Africa, but also to large parts of Asia, South and Central America, Arabia and the Mediterranean region.
However, the cases mentioned have nothing to do with Covid-19 disease. A PCR test result leading to the prophylactic prescription of HCQ is sufficient to cause severe disease in up to one third of the people from high-risk populations treated in this way.
HCQ treatment for G6PD deficiency is a dangerous malpractice
This could be remedied immediately if all treating physicians worldwide were informed about the contraindication of HCQ. However, the WHO, the CDC, the ECDC, the Chinese SARS specialists, the medical associations, the drug authorities and the German government and its advisors are carelessly neglecting to inform the public. In view of the ongoing programmes, this appears to be gross negligence.
It is a malpractice to treat people with G6PD deficiency with high-dose chloroquine derivatives or other drugs known to be dangerous for them. Under the WHO label "'Solidarity' clinical trial for COVID-19 treatments", healthy people are exposed in a hurry to authorised, life-threatening experiments. Hundreds of clinical trials, mostly worthless observational studies with parallel approaches, very often also run with HCQ as one of the alternatives.
German drug legislation prohibits the use of unauthorised drugs, but the government still encourages this. A non-validated test that is not approved for diagnostic purposes provides the pretext for the use of life-threatening medication – given an infectious disease where there is still no evidence that it poses serious risks beyond the risk of the annual flu epidemic.
At full throttle into the catastrophe
The dangers of this epidemic are presented with the help of scientific imposture. An unsuitable test from Berlin provides the pretext for deadly measures all over the world. The consequences of these mistakes lead to emergencies in many regions, which are attributed to an epidemic. This creates precisely the wave of fear so many in business and politics are now riding and which threatens to bury our fundamental rights.
The public, the media and the medical community hardly seem to be surprised that in New York and other centres more than twice as many "African Americans" die as would be expected due to their population share. Even in the studies of deaths in the USA and elsewhere, the risk posed by G6PD deficiency is almost always ignored or forgotten.
When sought-after virologists and other experts have been announcing for a long time that there will be a wave of deaths and terrible conditions in the cities in Africa, do they know about these connections? Or are there other provable reasons that justify such momentous prophecies? Finally: Is all this just a matter for science or also for public prosecutors and courts?
Note from the editor: Further information and graphics can be found on the author's website.
About the author: Dr. med. Wolfgang Wodarg, born in 1947, is an internist and pulmonary physician, specialist for hygiene and environmental medicine as well as for public health and social medicine. After his clinical activity as an internist, he was, among other things, a public health officer in Schleswig-Holstein, Germany for 13 years, at the same time lecturer at universities and technical colleges and chairman of the expert committee for health-related environmental protection at the Schleswig-Holstein Medical Association; in 1991 he received a scholarship at the Johns Hopkins University, Baltimore, USA (epidemiology).
As a member of the German Federal Parliament from 1994 to 2009, he was initiator and speaker in the Enquête Commission "Ethics and Law of Modern Medicine", member of the Parliamentary Assembly of the Council of Europe, where he was chairman of the Subcommittee on Health and deputy chairman of the Committee on Culture, Education and Science. In 2009, he initiated the Committee of Inquiry into WHO's role in H1N1 (swine flu) in Strasbourg, where he remained as a scientific expert after leaving Parliament. Since 2011 he has been working as a freelance university lecturer, doctor and health scientist and was a volunteer member of the board and head of the health working group at Transparency International Germany until 2020.
The artemisinin compound takes advantage of cancer cell's high iron levels. Artemisinin is highly toxic in the presence of iron, but harmless otherwise. Cancer cells need a lot of iron to maintain the rapid division necessary for tumor growth.
Since too much free-floating iron is toxic, when cells need iron they construct a special protein signal on their surfaces. The body's machinery then delivers iron, shielded with a protein package, to these signals proteins. The cell then swallows this bundle of iron and proteins.
Artemisinin alone is fairly effective at killing cancer cells. It kills approximately 100 cancer cells for every healthy cell, about ten times better than current chemotherapies. To improve those odds, the researchers added a small chemical tag to artemisinin that sticks to the "iron needed here" protein signal. The cancer cell, unaware of the toxic compound lurking on its surface, waits for the protein machinery to deliver iron molecules and engulfs everything -- iron, proteins and toxic compound.
Once inside the cell, the iron reacts with artemisinin to release poisonous molecules called free radicals. When enough of these free
radicals accumulate, the cell dies.
"The compound is like a little bomb-carrying monkey riding on the back of a Trojan horse," said Henry Lai, UW bioengineering professor and
co-author of the study.
The compound is so selective for cancer cells partly due to their rapid multiplication, which requires high amounts of iron, and partly because cancer cells are not as good as healthy cells at cleaning up free-floating iron.
"Cancer cells get sloppy at maintaining free iron, so they are more sensitive to artemisinin," Sasaki said.
My current research project is Clifford Algebra. My current engineering work involves embedded software and hardware design of high end audio preamps and amplifiers for Bryston/Axiom. My old engineering projects: (hires)
(website), (old picture of my lab). My old consulting company: website and resume. This blog contains also the essays, articles and debates on human nutrition (high animal fat low carb since 1999), science and other interesting topics and heresies (all of which hugely beneficial). I welcome debates and discourage conformity of any kind. Other interesting topic: human -to-primate social regression mediated by regressive collectivism (link), and fraud cases in medical and other research.
Climate Attribution In Greece
-
Climate scientists have determined that the fires in Greece this summer
were caused by the burning of fossil fuels, rather than the hundreds of
arsonists w...
The Journal of Empiricism
-
When I used to work at the UK Meteorological Office, I was often in their
library when work permitted. That was in the old building in Bracknell, a
build...
The Journal of Empiricism
-
When I used to work at the UK Meteorological Office, I was often in their
library when work permitted. That was in the old building in Bracknell, a
build...
7 Reasons Why Your Tech Blog Isn’t Succeeding
-
It is exciting to start a tech blog. Your mind projects thousands of
visitors to your site on a daily basis, and reads your reviews on new tech
devices, pr...
Protons (82) Size matters
-
Here's the next paper:
Obese adipocytes show ultrastructural features of stressed cells and die of
pyroptosis
I would suggest that the first of many probl...
The Cover up – Part One (context)
-
The Cover-up – Part One (context) A cover up. Yes, I know, I have
repeatedly said that I do not believe there was a great world-wide
conspiracy around COVI...
there is no “reset” – just live forward!
-
If you’re an intense person by nature, it’s likely that up to 75% of your
life energy every minute, every hour, every day is automatically…
The Prostate and its Discontents
-
This post originally appeared for subscribers only on my Patreon blog
(October 31). If you appreciate my occasional writing on science and stuff subscribe...
Akathisia
-
I recently recorded an episode of my podcast with my dad Jordan Peterson to
talk about what happened to him and my family in the last year. The
following...
Iron: an underrated factor in aging
-
My article, “Iron: an underrated factor in aging” has been published by the
journal Aging. The abstract: Iron is an essential element for virtually all
l...
Farewell, for now
-
“Ah, what an age it is When to speak of trees is almost a crime For it is a
kind of silence against injustice.” –Bertolt Brecht (1898-1956) In my
professio...
Leaving Facebook After ~11 years
-
This past week my wife and I engaged in the following activity:
#deletefacebook
Here’s excepts from text shared with friends and family:
You are being f-...
Twitter jail!
-
Well hello everyone :)
I have not blogged in a year! Feels rather odd to be honest; and to think,
this used to be MY platform.
While i have been consider...
Warning to Gay and Lesbian Movements
-
*Warning to Gay and Lesbian Movements.*
(Polish version - see below. Wersja Polska - poniżej)
As LGBT movement became radicalized and more visible than ever...
Ketosis Without Starvation: the human advantage
-
I recently had the honour to speak at Low Carb Breckenridge 2018. You can
find the video here. Below are my slides, notes, and references.
--------------...
Fasting Insulin
-
A blood test for fasting insulin can be one of the most important that you
get. It’s important because it shows the degree of insulin resistance: […]
Delegalize compulsory purchase of all types of insurance, including car and health service!
Delegalize health overseeing authorities and ban anti-competitive practices in the health services!
Delegalize manipulation of interest rate that robs the savers and enriches the large banks and governments.
Down with the dictate of shallow superficial people!
A critical period for children's education is age 7-14. Anything they learn during that period will be "weaponized" for the rest of their lives. Do not let them socialize during this period. Slow down their puberty past the age of 14 using low carb high animal fat diet!
Total Pageviews
Lunar Calendar 13
...
...
Moon Calendar: 13 months of 4 weeks of 7 days
Upper table: normal calendar dates (red numbers)
and the corresponding Moon Calendar dates (black) and (blue)
Lower table: Moon Months (1-13) and Moon Calendar dates
Thapsia garganica
